G. Schiller

G. Schiller, D. Winston, A. Molina, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transfusion‐associated graft‐versus‐host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second‐degree relative, and a survey of predisposing factors

G. Schiller, D. Sayah, R. B. Wallace, 1993, Transfusion.

Diagnosis of Fatal Human Case of St. Louis Encephalitis Virus Infection by Metagenomic Sequencing, California, 2016

P. Vespa, L. Coffey, R. Humphries, 2017, Emerging infectious diseases.

New cancers after autotransplantations for multiple myeloma.

A. Krishnan, S. Lonial, P. Hari, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

How to address second and therapy‐related acute myelogenous leukaemia

G. Schiller, C. Oliai, 2020, British journal of haematology.

A Critical Reappraisal of Gastrointestinal Complications of Allogeneic Bone Marrow Transplantation

R. Gale, G. Schiller, 1992, Cell transplantation.

Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors

S. Feig, M. Territo, G. Schiller, 1994, British journal of haematology.

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

J. Cortes, J. Kolitz, R. Stone, 2016 .

Autologous bone marrow transplantation in acute leukemia.

G. Schiller, B. Spellberg, 1999, Hematology/oncology clinics of North America.

Myelodysplasia

M. Wadleigh, G. Schiller, N. Reese, 2001 .

Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling

P. Bowers, Martina Roos, G. Schiller, 2019 .

Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.

S. Jagannath, G. Schiller, R. Sobecks, 2007 .

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

B. Coiffier, H. Gómez, P. Zinzani, 2012, The Lancet. Oncology.

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Patricia A. Young, Christopher M. Walthers, S. de Vos, 2022, medRxiv.

Vaccine-Associated Measles in a Hematopoietic Cell Transplant Recipient: Case Report and Comprehensive Review of the Literature

G. Schiller, D. Uslan, A. Multani, 2021, Open forum infectious diseases.

Outcome of transplantation for myelofibrosis.

N. Kröger, M. Horowitz, R. Gale, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

E. Estey, Chunaram Choudhary, A. Gratwohl, 2005, Blood.

Allelotype analysis in the evolution of chronic myelocytic leukemia.

H. Koeffler, H. Mizoguchi, G. Schiller, 1997, Blood.

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

A. Krishnan, W. Wood, P. Hari, 2015, Bone Marrow Transplantation.

Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma

G. Schiller, J. Harousseau, M. Attal, 2004 .

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

P. Westervelt, P. Fenaux, H. Fingert, 2014, Leukemia research reports.

SELECTIVE DEPLETION OF CD8+ CELLS FOR PREVENTION OF GRAFT‐VERSUS-HOST DISEASE AFTER BONE MARROW TRANSPLANTATION A RANDOMIZED CONTROLLED TRIAL

T. Reichert, M. Selch, J. Giorgi, 1994, Transplantation.

Myelodysplastic syndrome: An update on diagnosis and therapy

G. Schiller, A. Koppel, 2009, Current hematologic malignancy reports.

Myelodysplastic syndrome: An update on diagnosis and therapy

G. Schiller, A. Koppel, 2008, Current oncology reports.

High-risk acute myelogenous leukemia: treatment today ... and tomorrow.

G. Schiller, 2013, Hematology. American Society of Hematology. Education Program.

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

J. Dipersio, G. Schiller, A. Cashen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

N. Daver, M. Levis, J. Altman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

F. Uckun, G. Schiller, C. Cogle, 2019, Cancers.

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

R. Larson, G. Martinelli, J. Cortes, 2016 .

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.

G. Schiller, Pinkal M. Desai, Pamela Tuttle, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

J. Hainsworth, G. Schiller, D. Rizzieri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

When a gold standard is made of tin.

G. Schiller, 2010, Blood.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

H. Kantarjian, G. Martinelli, J. Cortes, 2018, Blood.

Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen

Patricia A. Young, S. de Vos, G. Schiller, 2020, Clinical Lymphoma Myeloma and Leukemia.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

P. Venugopal, H. Kantarjian, G. Garcia-Manero, 2012, The Lancet. Oncology.

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

S. Verstovsek, C. Brooks, M. Talpaz, 2018, Blood.

A slow-go prognosis for older patients with newly diagnosed AML.

G. Schiller, 2021, Blood.

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.

G. Schiller, S. Coutre, L. Damon, 2018, Journal of adolescent and young adult oncology.

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Tallman, B. Sandmaier, M. Tallman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL

D. Scheinberg, P. Maslak, M. Kalaycio, 2005 .

Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.

G. Schiller, Guneet Kaleka, 2021, Leukemia research.

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Jennifer A. Smith, G. Acton, H. Kantarjian, 2014 .

Multiple myeloma clones are derived from a cell late in B lymphoid development.

A. Lichtenstein, G. Schiller, J. Berenson, 1995, Current topics in microbiology and immunology.

Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, P. Hari, J. Bolaños-Meade, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML).

J. Dipersio, G. Schiller, A. Cashen, 2006 .

Allogeneic transplantation as therapy for acute myelogenous leukemia in the elderly.

G. Schiller, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ph1‐chromosome positive acute lymphoblastic leukemia: Is t(9;22) the initial abnormality?

R. Gale, G. Schiller, I. Aurer, 1993, American journal of hematology.

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.

J. Cortes, J. Kolitz, J. Lancet, 2021, Blood advances.

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

G. Martinelli, M. Tallman, M. Levis, 2013 .

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

M. Cazzola, H. Deeg, R. Schlenk, 2020, Leukemia.

MPN-377: Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2020 .

B-cell acute lymphoblastic leukemia as a secondary malignancy following diffuse large B-cell lymphoma

G. Schiller, A. Bejjani, D. Gaut, 2019, Hematology reports.

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

S. Tuchman, N. Callander, G. Schiller, 2021, British Journal of Cancer.

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

M. Arbushites, J. Dipersio, M. Perales, 2020, Blood advances.

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

A. Barrett, M. Horowitz, J. Wingard, 2009, Blood.

Posaconazole as Salvage Therapy for Zygomycosis

M. Schuster, R. Kryscio, J. Wingard, 2006, Antimicrobial Agents and Chemotherapy.

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

G. Ahmann, R. Fonseca, S. Jagannath, 2016 .

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

G. Ahmann, R. Fonseca, S. Jagannath, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver.

R. Busuttil, M. Territo, G. Schiller, 1996, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma

A. Lichtenstein, G. Schiller, J. Berenson, 1998, Bone Marrow Transplantation.

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.

J. Cortes, J. Kolitz, J. Lancet, 2021, The Lancet. Haematology.

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

J. Perfect, P. Pitisuttithum, J. Graybill, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

S. Jagannath, J. Hardwick, G. Schiller, 2012, Clinical lymphoma, myeloma & leukemia.

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

S. Jagannath, G. Schiller, R. Sobecks, 2008 .

A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature

G. Schiller, M. Sharifian, C. Tirado, 2016, Biomarker Research.

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

S. Tuchman, N. Callander, G. Schiller, 2020, EJHaem.

Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?

P. Maslak, M. Kalaycio, K. Panageas, 2013, Cancer.

Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Q. Jiang, G. Barosi, F. Passamonti, 2017, Leukemia.

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)

J. Dipersio, G. Schiller, A. Cashen, 2008 .

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

D. Siegel, W. Pierceall, S. Srinivasan, 2019, British journal of haematology.

Exclusive use of acid citrate dextrose for anticoagulation during extracorporeal photopheresis in patients with contraindications to heparin: An effective protocol

G. Schiller, A. Ziman, P. Bumerts, 2008, Journal of clinical apheresis.

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

N. Daver, M. Levis, J. Altman, 2021, Blood.

CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency

M. Territo, G. Schiller, D. Winston, 2010, Bone Marrow Transplantation.

Aplastic anemia complicating orthotopic liver transplantation

R. Busuttil, P. Seu, G. Schiller, 1997, Hepatology.

transplantation superior to HLA-identical siblings for hematopoietic stem cell The graft-versus-leukemia effect using matched unrelated donors is not

J. Wingard, P. McCarthy, S. Spellman, 2011 .

Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.

O. Frankfurt, G. Schiller, P. Stiff, 2021, Blood.

Comparison of twin and autologous transplants for multiple myeloma.

R. Fonseca, P. Hari, R. Kyle, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

R. Houot, A. Logan, M. Bishop, 2022, Journal of hematology & oncology.

Vincristine Sulfate Liposomes Injection (Marqibo®) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

G. Schiller, S. Goldberg, L. Damon, 2011 .

Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components

A. Nooka, G. Schiller, M. Sehl, 2022, Transfusion.

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

D. Siegel, W. Pierceall, D. Reece, 2020, Leukemia.

Standardized protocol to identify high‐risk patients undergoing therapeutic apheresis procedures

G. Schiller, A. Ziman, Qun Lu, 2008, Journal of clinical apheresis.

Interferon-α induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo

C. Sawyers, J. Said, G. Schiller, 2002, Leukemia.

Treatment of Scedosporium apiospermum brain abscesses with posaconazole.

I. Mellinghoff, G. Schiller, G. Mukwaya, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.

A. Lichtenstein, G. Schiller, J. Berenson, 1996, Bone marrow transplantation.

Acquired abnormalities of platelet function.

G. Schiller, Steven C. Cramer, 1991, The New England journal of medicine.

Myelodysplasic syndromes: a comprehensive review.

G. Schiller, D. Catenacci, 2005, Blood reviews.

How to Teach the Topic of Acute Myelogenous Leukemia: Recommendations for Achieving Curricular Milestones

G. Schiller, E. Muchmore, 2014 .

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

A. Wei, S. de Botton, Sangmin Lee, 2022, The Lancet. Haematology.

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

H. Döhner, M. Tallman, C. Dinardo, 2017 .

Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

R. Larson, J. Cortes, M. Levis, 2015 .

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Robert K. Stuart, Antje Hoering, Arthur C. Louie, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

R. Larson, G. Martinelli, J. Cortes, 2017, The Lancet. Oncology.

Chronic Leukemias and Lymphomas

G. Schiller, 2002 .

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.

M. Territo, G. Schiller, M. Schuster, 2000, The American journal of medicine.

Gene Therapy in Patients with Transfusion‐Dependent β‐Thalassemia

C. von Kalle, J. Rasko, D. Teachey, 2018, The New England journal of medicine.

Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy.

G. Schiller, R. L. Kleynberg, 2012, Clinical advances in hematology & oncology : H&O.

Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.

M. Territo, G. Schiller, D. Winston, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment.

R. Paquette, M. Territo, G. Schiller, 2004, Blood.

Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

O. Frankfurt, S. Kambhampati, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

J. Klein, M. Tallman, A. Keating, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

R. Larson, H. Dombret, R. Foà, 2015, The Lancet. Oncology.

Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

R. Houot, A. Logan, F. Milletti, 2021 .

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2019, The New England journal of medicine.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

J. Cortes, C. Abboud, G. Schiller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar HGB-204 Study

J. Rasko, E. Vichinsky, G. Schiller, 2018, Blood.

Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar Hgb-204 Study

J. Rasko, E. Vichinsky, G. Schiller, 2017 .

Infrequent Alterations of the RARa Gene in Acute Myelogenous Leukemias , Retinoic Acid-Resistant Acute Promyelocytic Leukemias , Myelodysplastic Syndromes , and Cell Lines

Carl W. Miller, P. Pelicci, C. Bartram, 2002 .

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Arnaud Pigneux, Gary Acton, Michael Heuser, 2015, The Lancet. Oncology.

Treatment of resistant disease.

G. Schiller, 1998, Leukemia.

Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate.

Richard, G. Schiller, E. Landaw, 1992, Blood.

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

P. Venugopal, M. Buyse, G. Gaidano, 2021, Cancer.

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma

S. Jagannath, T. Zimmerman, M. Oken, 2009, Leukemia & lymphoma.

Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults.

G. Schiller, Brian D. Friend, 2021, Blood reviews.

Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults.

G. Schiller, Brian D. Friend, 2017, Blood reviews.

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

M. Erlander, S. Silberman, G. Schiller, 2020, Clinical Cancer Research.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

E. Estey, D. Gilliland, D. Gilliland, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

T. Grogan, W. Dalton, R. Dorr, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

G. Schiller, M. Sharifian, C. Tirado, 2016, Biomarker Research.

Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.

M. Territo, G. Schiller, D. Bruckner, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Scott E. Smith, A. Nagler, H. Kantarjian, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia

M. Territo, G. Schiller, Stephen S. Nimer, 1993, American journal of hematology.

Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.

A. Lichtenstein, G. Schiller, J. Berenson, 1995, Blood.

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

J. Byrd, R. Collins, N. Heerema, 2020, Nature Medicine.

Biologic Therapy of Leukemia

G. Schiller, 2003, Contemporary Hematology.

Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience.

Kathleen E. Fenerty, S. de Vos, G. Schiller, 2021, Clinical lymphoma, myeloma & leukemia.

Duodenal Lymphoma: A Rare and Morbid Tumor

J. Hiatt, G. Schiller, P. Chestovich, 2007, The American surgeon.

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.

H. Kantarjian, J. Cortes, R. Stone, 2004 .

Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.

R. Collins, P. Hari, M. Maris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.

J. Klein, M. Horowitz, R. Gale, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone marrow aplasia associated with proliferation of large granular lymphocytes and subsequent transformation to acute lymphoblastic leukemia

F. Naeim, G. Schiller, R. Champlin, 1989, American journal of hematology/oncology.

Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission

E. Collisson, R. Paquette, M. Territo, 2003, Leukemia.

A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.

Alan M. Miller, J. Armitage, J. Vose, 2003, Blood.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

W. Wilson, I. Pastan, J. Delgado, 2018, Leukemia.

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

C. Schiffer, H. Kantarjian, J. Cortes, 2012, Leukemia.

Conjugation of an anti–transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells

T. Daniels, Tracie Delgado, G. Helguera, 2007, Molecular Cancer Therapeutics.

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.

S. Morrison, T. Daniels, G. Helguera, 2006, Blood.

The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma.

A. Lichtenstein, G. Schiller, J. Berenson, 1994, Blood.

Comparison o f P reparative R egimens i n T ransplants f or Children W ith A cute L ymphoblastic L eukemia

J. Klein, M. Horowitz, R. Gale, 2000 .

Salvage second hematopoietic cell transplantation in myeloma.

J. Vose, A. Krishnan, S. Lonial, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

M. Levis, K. Pratz, J. Altman, 2020 .

Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.

S. Nimer, M. Territo, G. Schiller, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.

B. Bonavida, G. Schiller, C. Ng, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma.

G. Pinkus, H. Koeffler, J. Said, 1997, Blood.

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

S. Verstovsek, C. Brooks, A. Tefferi, 2021, Blood.

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

D. Siegel, D. Reece, A. Agarwal, 2020 .

Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

D. Siegel, D. Reece, G. Schiller, 2018 .

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2021 .

Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence

M. Cazzola, K. Döhner, T. Barbui, 2013 .

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.

J. Cortes, J. Kolitz, J. Lancet, 2020 .

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

M. Heuser, J. Cortes, B. Smith, 2019, Clinical Lymphoma Myeloma and Leukemia.

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

M. Heuser, J. Cortes, B. Smith, 2019, Journal of Clinical Oncology.

Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)

P. Westervelt, P. Fenaux, H. Fingert, 2010 .

Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia

David A. Williams, G. Vercellotti, G. Schiller, 2019, Blood.

IS THE INTERNATIONAL STAGING SYSTEM SUPERIOR TO THE DURIE SALMON STAGING SYSTEM? A COMPARISON IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT

P. Hari, R. Kyle, D. Reece, 2009, Leukemia.

Chronic myelogenous leukemia stem cells require cell-autonomous pleiotrophin signaling.

P. Bowers, Martina Roos, G. Schiller, 2019, The Journal of clinical investigation.

Bone marrow transplantation vs. high-dose cytorabine-based consolidation chemotherapy for acute myelogenous leukemia. A long-term follow-up study of quality-of-life measures of survivors.

G. Schiller, D. Wellisch, T. Belin, 1996, Psychosomatics.

Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Non-Malignant Diseases

M. Sorror, E. Guinan, M. Krem, 2022, Transplantation and Cellular Therapy.

Disease characteristics of diffuse large B‐cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience

G. Schiller, T. Romero, D. Gaut, 2020, Hematological oncology.

Interleukin-2 Treatment of Acute Leukemia

P. Kabos, G. Schiller, 2003 .

Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research

J. Szer, M. Tallman, K. Ballen, 2013, Haematologica.

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

R. Larson, G. Martinelli, M. Levis, 2022, Blood.

Acute Myeloid Leukemia: Mutations Blocking Differentiation Lead to Distinct Leukemic Subtypes

G. Schiller, A. Cummings, Darren Pan, 2019, Human Pathobiochemistry.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

M. Konopleva, H. Kantarjian, A. Lane, 2022, Blood.

Trial in Progress: Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

A. Logan, C. Tseng, G. Schiller, 2022, Blood.

Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia

M. Sekeres, G. Schiller, 2009 .

Evolving treatment strategies in patients with high-risk acute myeloid leukemia

G. Schiller, 2014, Leukemia & lymphoma.

H. Kantarjian, J. Cortes, R. Stone, 2006 .

Diminished durability of chimeric antigen receptor T‐cell efficacy with severe or prolonged postinfusion cytopenias

Patricia A. Young, M. Sim, G. Schiller, 2022, American journal of hematology.

Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

M. Levis, A. Fathi, J. Altman, 2021 .

PS1036 UPDATED RESULTS FROM A PHASE 1 STUDY OF GILTERITINIB IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED AML

M. Levis, K. Pratz, J. Altman, 2019, HemaSphere.

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

S. de Botton, A. Fathi, J. Altman, 2022, Blood.

Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study

M. Berger, D. Ludwig, G. Schiller, 2020 .

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

N. Daver, M. Levis, J. Altman, 2020 .

Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.

C. Sawyers, J. Said, G. Schiller, 2002, Leukemia.

A randomized study of intermediate versus conventional‐dose cytarabine as intensive induction for acute myelogenous leukaemia

M. Territo, G. Schiller, R. Champlin, 1992, British journal of haematology.

Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells.

G. Schiller, J. Berenson, R. Vescio, 2000, Blood.

Acute Myeloid Leukemia: How Do We Measure Success?

G. Schiller, Joshua P. Sasine, 2016, Current Hematologic Malignancy Reports.

Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry.

J. Klein, M. Horowitz, R. Gale, 2000, Blood.

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Jennifer A. Smith, H. Kantarjian, J. Cortes, 2016 .

J. Sierra, M. Tallman, R. Gale, 2008, Blood.

Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.

T. Duong, Aaron Burkenroad, G. Schiller, 2020, Leukemia research.

Identifying risk factors associated with worse outcomes in adolescents and young adults undergoing hematopoietic stem cell transplantation

D. Elashoff, D. Markovic, G. Schiller, 2019, Pediatric blood & cancer.

The impact of T-cell depletion on the effects of HLA DRβ1 and DQβ allele matching in HLA serologically identical unrelated donor bone marrow transplantation

S. Feig, D. Gjertson, B. Andersson, 1997 .

The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.

S. Feig, D. Gjertson, B. Andersson, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.

S. Vollset, S. Nimer, G. Schiller, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma

Tuan S. Nguyen, P. Richardson, C. Kaiser, 2016, Clinical Cancer Research.

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.

M. Territo, G. Schiller, C. Emmanouilides, 2004, Clinical lymphoma.

lymphoblastic leukemia in first complete remission Unrelated donor transplants in adults with Philadelphia-negative acute

J. Sierra, R. Gale, M. Bishop, 2011 .

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

S. Solomon, D. DeAngelo, S. O'brien, 2010, Journal of Clinical Oncology.

Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.

E. Collisson, R. Paquette, M. Territo, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Preventive strategies for invasive Aspergillus in acute myelogenous leukemia.

G. Schiller, 2016, Clinical advances in hematology & oncology : H&O.

Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.

J. Sierra, A. Zander, M. Horowitz, 2006, Biology of Blood and Marrow Transplantation.

Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.

M. Krem, Stephanie J. Lee, K. Syrjala, 2021, Transplantation and cellular therapy.

Myelodysplasia – therapeutic response to novel therapy and the need for new diagnostic groups

G. Schiller, 2003, Leukemia.

PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

J. Cortes, G. Schiller, K. Seiter, 2019, HemaSphere.

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

H. Kantarjian, J. Cortes, Sangmin Lee, 2018, Blood.

Nonmyeloablative approaches to the treatment of sickle hemoglobinopathies.

G. Schiller, R. Amado, 2000, Seminars in oncology.

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

D. Siegel, D. Reece, A. Agarwal, 2022, Leukemia & lymphoma.

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2020 .

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

D. Siegel, D. Reece, A. Agarwal, 2018, Blood.

Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians

M. Sorror, M. Pasquini, M. Thakar, 2022, Leukemia & lymphoma.

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2020 .

Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission

M. Territo, G. Schiller, A. Alavi, 2012, Cancers.

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non‐Hodgkin's lymphoma

B. Nathwani, A. Tulpule, G. Schiller, 1998, Cancer.

Hairy cell leukemia and sarcoidosis: a case report and review of the literature

J. Said, G. Schiller, S. Pal, 2003, Leukemia.

Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib

G. Schiller, Edward Ha, D. Ng, 2019, Annals of Hematology.

Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study

J. Rasko, M. Cavazzana‐Calvo, E. Vichinsky, 2016, Blood.

High-Intensity Induction in the Elderly

G. Schiller, 2015, Acta Haematologica.

Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

S. Nimer, M. Territo, G. Schiller, 1992 .

Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia.

H. Koeffler, H. Mizoguchi, G. Schiller, 1998, Blood.

Absence of microsatellite instability during the progression of chronic myelocytic leukemia

H. Koeffler, H. Mizoguchi, G. Schiller, 1997, Leukemia.

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

N. Daver, U. Borate, G. Hobbs, 2022, Blood.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

R. Gale, Q. Jiang, R. Mesa, 2016, Leukemia.

Threshold dose of autologous CD34-positive peripheral blood progenitor cells required for engraftment after myeloablative treatment for multiple myeloma

L. Rosen, G. Schiller, J. Berenson, 1994 .

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia

A. Shamas-Din, M. Minden, S. Kambhampati, 2016, Cancer medicine.

Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.

M. Sorror, M. Krem, M. Pasquini, 2022, Transplantation and Cellular Therapy.

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

D. Siegel, W. Pierceall, D. Reece, 2018, Blood.

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

D. Reece, A. Agarwal, G. Schiller, 2017 .

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

P. Richardson, C. Kaiser, N. Raje, 2012 .

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

S. Tuchman, N. Callander, M. Leiba, 2021, Blood.

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

R. Larson, G. Martinelli, M. Levis, 2022, Transplantation and cellular therapy.

AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results.

M. Levis, K. Pratz, J. Altman, 2022, Clinical Lymphoma, Myeloma & Leukemia.

A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.

O. Frankfurt, F. Ravandi, J. Pagel, 2018 .

Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.

R. Larson, N. Russell, G. Martinelli, 2014 .

Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

Scott E. Smith, H. Kantarjian, D. B. Yehuda, 2010 .

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission

J. Cortes, J. Kolitz, G. Schiller, 2020 .

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Breeze, M. Dimopoulos, R. Vij, 2021, BMC cancer.

Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).

T. Zimmerman, A. Chanan-Khan, R. Hohl, 2004 .

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

S. Tuchman, N. Callander, G. Schiller, 2022, Blood.

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

S. Tuchman, N. Callander, G. Schiller, 2021, EJHaem.

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

S. Tuchman, N. Callander, G. Schiller, 2021, Blood.

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

J. Shah, S. Tuchman, N. Callander, 2020 .

Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Jennifer A. Smith, G. Acton, H. Kantarjian, 2015 .

VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia

Michael Craig, Robert K. Stuart, Gary Acton, 2012 .

AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study

N. Daver, M. Levis, J. Altman, 2021 .

Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.

J. Cortes, C. Abboud, G. Schiller, 2008 .

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

J. Shah, S. Tuchman, N. Callander, 2020 .

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2020 .

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Shah, J. Breeze, M. Dimopoulos, 2020, BMC Cancer.

MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study

S. Verstovsek, R. Hoffman, M. Talpaz, 2021 .

Clinical Implications of Anti-CD19 Chimeric Antigen Receptors (CAR) T Cell Therapy in Acute Lymphoblastic Leukemia (ALL)

G. Schiller, A. Jazirehi, T. Dinh, 2017 .

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

D. Sullivan, G. Schiller, M. Sebag, 2018, Blood.

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

J. Kurtzberg, O. Frankfurt, D. Cilloni, 2023, Transplantation and cellular therapy.

A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

J. Cortes, Sangmin Lee, G. Schiller, 2018 .

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)

N. Heerema, R. Levine, B. Druker, 2022, Blood.

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

G. Garcia-Manero, C. Brooks, A. Tefferi, 2021, Blood.

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

S. Kambhampati, C. McMahon, G. Borthakur, 2022, Blood.

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

R. Collins, N. Heerema, R. Levine, 2023, Cancer.

Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

R. Larson, M. Konopleva, E. Jabbour, 2021, Blood.

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.

S. Verstovsek, C. Brooks, M. Talpaz, 2019, Journal of Clinical Oncology.

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2018, Blood.

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).

S. Verstovsek, C. Brooks, M. Talpaz, 2019, Journal of Clinical Oncology.

A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).

P. Trojer, S. Verstovsek, R. Hoffman, 2019, Journal of Clinical Oncology.

Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma

H. Rugo, J. Dipersio, G. Schiller, 1999 .

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

M. Sabatino, J. Rossi, M. Bishop, 2017 .

RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation

L. Lekakis, Z. DeFilipp, G. Schiller, 2022, Blood.

Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

R. Larson, H. Dombret, H. Kantarjian, 2014 .

Liposomal Cytarabine–Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review

G. Schiller, C. Oliai, Grant Howell, 2018, AntiCancer Research.

Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission

C. Sawyers, R. Paquette, M. Territo, 2001, Leukemia.

Postremission therapy of acute myeloid leukemia in older adults.

G. Schiller, 1996, Leukemia.

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

J. Shah, S. Tuchman, N. Callander, 2019, Blood.

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

J. Shah, S. Tuchman, G. Schiller, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

S. Tuchman, G. Schiller, R. Kotb, 2023, Clinical lymphoma, myeloma & leukemia.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

R. Larson, H. Dombret, R. Foà, 2015, The Lancet. Oncology.

High-risk acute myelogenous leukemia: treatment today ... and tomorrow.

G. Schiller, 2013, Hematology. American Society of Hematology. Education Program.

ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)

M. Kersten, G. Schiller, W. Wierda, 2016 .

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

J. Byrd, N. Heerema, R. Levine, 2019, Blood.

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

J. Dipersio, G. Schiller, A. Cashen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

B. Coiffier, H. Gómez, P. Zinzani, 2009 .

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

J. Cortes, J. Kolitz, R. Stone, 2018, Blood.

B. Coiffier, H. Gómez, P. Zinzani, 2012, The Lancet. Oncology.

Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.

P. Richardson, N. Raje, R. Hohl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

S. Solomon, D. DeAngelo, S. O'brien, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

R. Houot, A. Logan, M. Bishop, 2023, Journal for ImmunoTherapy of Cancer.

Acute Myeloid Leukemia with Cup-Like Nuclear Inclusions, and FLT3-ITD andNPM1 Mutations

G. Schiller, Joshua P. Sasine, Rena R. Xian, 2017 .